Table 3.
Differentially expressed genes in adenomatous (low grade dysplasia, D1) versus normal colonic samples (differentially regulated in at least 2/6 patients)
| Gene (accession No) | Upregulated (fold increase) | Downregulated (fold increase) | Regulation |
| DNA-PK; DNA-PKCS (U35835) | 4.4 | ↑ 2 (6)* | |
| 11.5 | |||
| (M=7.95) | |||
| DNA topoisomerase II alpha (170kDa) (J04088) | 2.6 | ↑ 2 (6) | |
| 23 | |||
| (M=12.8) | |||
| rho GDP dissociation inhibitor 2; LY-GDI; ARHGDIB; GDID4 (L20688) | 3.0 | ↑ 2 (6) | |
| 24.0 | |||
| (M=13.5) | |||
| Laminin beta 1 (M61916) | 4.4 | ↑ 2 (6) | |
| 5.5 | |||
| (M=4.95) | |||
| Catenin (cadherin associated protein) beta 1 (88 kDa) (X87838) | 2.2 | ↑ 2 (6) | |
| 27.6 | |||
| (M=14.9) | |||
| Cyclin dependent kinase 6 X66365) | 6.8 | ↑ 2 (6) | |
| 12.1 | |||
| (M=9.45) | |||
| CDKN1A; melanoma differentiation associated protein 6; CIP1; WAF1 (U09579) | 29.5 | ↑ 2 (6) | |
| 42.5 | |||
| (M=36.0) | |||
| v-erb-b2 avian erythroblastic leukaemia viral oncogene homolog 3 (M29366) | 13.5 | ↑ 2 (6) | |
| 4.0 | |||
| (M=8.75) | |||
| BARD1 (U76638) | 2.6 | 5.4 | ↑ 2 (6)/↓ 2 (6) |
| 40.0 | 7.4 | ||
| (M=21.3) | (M=6.4) | ||
| Hepatoma derived growth factor (high mobility group protein 1- like) (D16431) | 2.8 | ↑ 2 (6)/↓ 1 (6) | |
| 7.8 | 7.5 | ||
| (M=5.3) | |||
| Inhibitor of growth 1 family member 1 (AF001954) | 9.45 | ↑ 1 (6)/↓ 2 (6) | |
| 29.7 | 5.6 | ||
| (M=7.53) | |||
| Integrin alpha 6; VLA6, CD49F antigen (X53586) | 2.9 | ↑ 1 (6)/↓ 2 (6) | |
| 2.25 | 51.0 | ||
| (M=26.95) | |||
| Urokinase-type plasminogen activator receptor GPI-anchored form precursor (U-PAR); monocyte activation MO3; CD87 antigen (U08839) | 24.7 | ↓ 2 (6) | |
| 2.6 | |||
| (M=13.65) | |||
| Type II cytoskeletal 8 keratin (KRT8); cytokeratin 8 (K8; CK8) (M34225) | 2.4 | ↓ 2 (6) | |
| 3.3 | |||
| (M=2.85) |
Values represent the mean up- or downregulation of all experiments in each patient.
*2 (6) indicates 2 of 6 patients regulated differentially.
M, median; DNA-PK, DNA dependent protein kinase; DNA-PKCS, DNA-PK catalytic subunit; CDKN1A cyclin dependent kinase inhibitor 1 A; CIP1, CDK-interacting protein 1; BARD1, BRCA1 associated RING domain.